Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Mitchel L. Zoler, PhD

Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler

News

Widespread liver disease missed in patients with T2D

Author:
Mitchel L. Zoler, PhD
Publish date: January 22, 2021

New evidence showing how common fatty liver disease and fibrosis are in patients with type 2 diabetes triggers a broadened “call to action.”

  • Read More

News

Cardiometabolic Center Alliance promotes multiorgan, integrated T2D treatment

Author:
Mitchel L. Zoler, PhD
Publish date: January 20, 2021

Begun in 2020, the Cardiometabolic Center Alliance seeks to transform preventive care for patients with T2D with an aggressive, multidisciplinary...

  • Read More

News

Sotagliflozin’s trial data receives FDA welcome for NDA filing

Author:
Mitchel L. Zoler, PhD
Publish date: January 14, 2021

The SOLOIST and SCORED trials of the SGLT1/2 inhibitor sotagliflozin did not proceed as planned, but the FDA says it will accept the results in an...

  • Read More

News

Far too few with treatment-resistant hypertension get hormone test

Author:
Mitchel L. Zoler, PhD
Publish date: December 31, 2020

“Testing rates also did not change meaningfully over nearly 2 decades ... despite an increasing number of guidelines recommending testing for...

  • Read More

News

Twincretin ‘impressive’: Topline data from phase 3 trial in diabetes

Author:
Mitchel L. Zoler, PhD
Publish date: December 14, 2020

Tirzepatide, the first dual GIP and GLP-1 receptor agonist in advanced testing, showed potent antihyperglycemic and weight loss effects in the...

  • Read More

News

FDA approves liraglutide for adolescents with obesity

Author:
Mitchel L. Zoler, PhD
Publish date: December 10, 2020

The Food and Drug Administration okays daily, subcutaneous liraglutide for adolescents with obesity, the first...

  • Read More

News

Obesity phenotyping matches patients with more effective interventions

Author:
Mitchel L. Zoler, PhD
Publish date: December 4, 2020

A prospective, randomized study suggests obesity phenotyping can guide selection of more effective, tailored weight-loss drug regimens.

  • Read More

Article

Finerenone’s heart benefits hold up in T2D patients without CVD

Author:
Mitchel L. Zoler, PhD
Publish date: November 24, 2020

In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...

  • Read More

News

First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D

Author:
Mitchel L. Zoler, PhD
Publish date: November 18, 2020

A pair of pivotal trials showed safety and efficacy for sotagliflozin for patients with type 2 diabetes, including novel benefits from an SGLT...

  • Read More

News

VTEs tied to immune checkpoint inhibitor cancer treatment

Author:
Mitchel L. Zoler, PhD
Publish date: November 17, 2020

Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...

  • Read More

News

Evinacumab, novel lipid-lowerer, extends promise in phase 2 results

Author:
Mitchel L. Zoler, PhD
Publish date: November 15, 2020

Evinacumab cuts LDL-C and triglycerides by boosting lipase activity. It showed safety and efficacy in patients with heterozygous FH.

  • Read More

News

Empagliflozin favorably reshaped left ventricles in HFrEF patients

Author:
Mitchel L. Zoler, PhD
Publish date: November 15, 2020

Results from two separate randomized studies showed empagliflozin treatment of patients with HFrEF produced significant heart remodeling.

  • Read More

News

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit

Author:
Mitchel L. Zoler, PhD
Publish date: November 13, 2020

Omecamtiv mecarbil safely met its primary efficacy endpoint in patients with heart failure with reduced ejection...

  • Read More

News

New eGFR equation ‘less biased’ by age, kidney function; some disagree

Author:
Mitchel L. Zoler, PhD
Publish date: November 10, 2020

The European Kidney Function Consortium equation surpasses existing equations by "resulting in generally lower bias across the spectrum of age and...

  • Read More

News

No link shown between thyroid dysfunction and heart failure

Author:
Mitchel L. Zoler, PhD
Publish date: November 10, 2020

Analysis of nearly 5,000 English heart failure patients showed no significant link between thyroid dysfunction...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close